HumaninvsMOTS-C

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Its discovery in 2001 was revolutionary — it was the first identified mitochondrial-derived peptide (MDP), challenging the long-held dogma that the mitochondrial genome only encodes 13 oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs. Humanin, along with MOTS-C and the SHLP peptides discovered later, established mitochondria as endocrine organelles.

Humanin exerts cytoprotective effects through multiple mechanisms. Extracellularly, it binds to a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha), and gp130 (the shared signaling subunit of the IL-6 receptor family). Activation of this complex triggers JAK/STAT3 signaling, which drives expression of anti-apoptotic genes (Bcl-2, Mcl-1) and cell survival programs. Intracellularly, humanin interacts directly with two pro-apoptotic proteins: it binds IGFBP-3, preventing IGFBP-3 from translocating to mitochondria and initiating apoptosis; and it binds BAX (Bcl-2-associated X protein), preventing BAX oligomerization and insertion into the outer mitochondrial membrane — the critical step in the intrinsic (mitochondrial) apoptosis pathway that releases cytochrome c and activates caspases.

Humanin also reduces cellular stress through multiple pathways. It decreases reactive oxygen species (ROS) production by optimizing mitochondrial electron transport chain function. It reduces endoplasmic reticulum (ER) stress by modulating the unfolded protein response (UPR). It improves insulin sensitivity through STAT3-mediated effects on hypothalamic signaling and peripheral insulin receptor substrate phosphorylation. Circulating humanin levels decline with age (approximately 40% reduction between youth and old age) and are inversely correlated with markers of age-related disease, suggesting that humanin decline contributes to the increased cellular vulnerability and apoptosis susceptibility seen in aging. Its most potent synthetic analogue, HNG (S14G-humanin), has a glycine-for-serine substitution at position 14 that increases cytoprotective potency approximately 1,000-fold.

MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded in the mitochondrial genome within the 12S rRNA gene. Its discovery in 2015 by Dr. Changhan David Lee at USC was groundbreaking because it demonstrated that the mitochondrial genome encodes functional peptides beyond the 13 oxidative phosphorylation subunits traditionally recognized — establishing mitochondria as endocrine organelles capable of producing signaling hormones.

MOTS-C's primary metabolic mechanism centers on activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. MOTS-C activates AMPK by increasing the AMP/ATP ratio through inhibition of the folate cycle and de novo purine biosynthesis pathway. Specifically, MOTS-C inhibits the folate/methionine cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase), leading to accumulation of the intermediate AICAR — which is itself an endogenous AMPK activator. This creates a feed-forward AMPK activation signal.

Activated AMPK triggers a cascade of metabolic adaptations that mimic exercise: increased glucose uptake via GLUT4 translocation (independent of insulin signaling), enhanced fatty acid oxidation through ACC phosphorylation and CPT-1 activation, stimulation of mitochondrial biogenesis via PGC-1α, and suppression of mTORC1-mediated protein synthesis to conserve energy. Under metabolic stress, MOTS-C translocates from the cytoplasm to the nucleus — a remarkable feat for a mitochondria-encoded peptide — where it directly regulates nuclear gene expression by interacting with antioxidant response elements (AREs) and NF-κB target genes. This nuclear translocation represents a novel mechanism of mitonuclear communication — the mitochondria literally sending a peptide messenger to the nucleus to coordinate the cellular stress response. MOTS-C levels decline with age in humans, correlating with the age-related decline in metabolic fitness, insulin sensitivity, and exercise capacity, making it a compelling target for metabolic aging intervention.